Science Around GLP-1 Drugs and Cancer Gets More Interesting

Science Around GLP-1 Drugs and Cancer Gets More Interesting

The Washington Post recently highlighted that the science around GLP-1 drugs and cancer is becoming more interesting. This observation reflects a growing body of research that is reshaping how researchers, clinicians, and health-conscious individuals think about these medications. Originally developed for type 2 diabetes and later approved for weight management, GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda) are now under intense scrutiny for their potential to influence cancer development and progression. This article unpacks the current state of the evidence, explores the mechanisms at play, and addresses the questions that patients and researchers are asking.

Background on GLP-1 Receptor Agonists

GLP-1 receptor agonists mimic the action of glucagon-like peptide-1, a hormone that stimulates insulin secretion, slows gastric emptying, and promotes satiety. By activating GLP-1 receptors throughout the body, these drugs produce significant metabolic effects beyond glucose control. Their widespread use has already led to a market that exceeded $20 billion in global sales in 2023, with projections continuing to climb.

However, as millions of people begin taking these drugs long term, understanding their safety profile becomes paramount. Cancer risk has been a persistent question since the early days of GLP-1 drug development. Animal studies showed that certain GLP-1 agonists could cause thyroid C-cell tumors in rodents, leading the U.S. Food and Drug Administration to require a black box warning for medullary thyroid carcinoma. But human data has been less clear, and recent large observational studies are now providing more nuanced answers.

The Emerging Cancer Connection

The Washington Post report captures a pivotal moment: the scientific conversation around GLP-1 drugs and cancer is no longer limited to thyroid safety concerns. Instead, it now includes the possibility that these medications might lower the risk of several common cancers.

A major catalyst for this shift was a study published in February 2025 in JAMA Network Open by researchers at the University of Texas Medical Branch. The team, led by Dr. Elizabeth A. Platz, analyzed electronic health records from more than 1.6 million patients with type 2 diabetes over a 15 year period. They compared those prescribed GLP-1 receptor agonists with similar patients taking other diabetes medications such as metformin, sulfonylureas, and insulin.

The results were striking. Patients using GLP-1 drugs had an 11% lower risk of developing obesity related cancers, including colorectal, breast, pancreatic, and ovarian cancers. The protective effect was strongest for colorectal cancer, where the risk reduction reached 18%.

Another study published in October 2024 in The Lancet Diabetes & Endocrinology followed more than 200,000 patients in the United Kingdom and found that semaglutide use was associated with a 14% reduction in overall cancer incidence compared to placebo, after adjusting for weight loss and other factors.

“We are beginning to see a pattern that is consistent across multiple large cohorts,” said Dr. Michael A. Nauck, a diabetes researcher at the Ruhr University Bochum in Germany, in an interview with the Washington Post. “The magnitude of the effect is modest but real, and it raises important questions about mechanism.”

Recent Evidence and Key Studies

The methodology behind these studies is critical to interpreting their results. Observational studies rely on real world clinical data, which can introduce confounding variables. For example, patients who are prescribed GLP-1 drugs may have better access to healthcare, adhere more closely to treatment, or lead healthier lifestyles than those on other medications. Researchers attempt to control for these factors through propensity score matching and multivariable regression, but residual confounding remains possible.

Dr. Platz and her team used a technique called “target trial emulation” to mimic the design of a randomized controlled trial. They matched patients on age, sex, body mass index, smoking status, and duration of diabetes. They also required a minimum of 12 months of drug exposure to avoid bias from early discontinuation.

A second notable study, published in December 2024 in Nature Communications, looked specifically at colorectal cancer. Researchers from Case Western Reserve University used data from more than 1.2 million patients in the U.S. Veterans Health Administration system. They reported that GLP-1 receptor agonist users had a 22% lower risk of colorectal cancer than users of other diabetes medications. The effect persisted across subgroups defined by age, race, and weight.

“This is one of the largest and most rigorous analyses to date,” commented Dr. Sanjay Rajagopalan, a cardiologist and co author of the study. “The consistency between different databases gives us confidence that the association is real.”

Mechanistic Explanations

If GLP-1 drugs do reduce cancer risk, how might they accomplish this? Several plausible mechanisms have been proposed.

Weight loss itself is a major factor. Obesity is a well established risk factor for at least 13 types of cancer, including colorectal, breast, endometrial, and esophageal cancer. The average weight loss observed with semaglutide in clinical trials is around 15% of body weight. Reducing adipose tissue lowers circulating levels of insulin, insulin like growth factor 1, leptin, and inflammatory cytokines all of which are implicated in tumor growth.

But weight loss alone may not tell the full story. GLP-1 receptors are expressed on many cell types, including immune cells and intestinal epithelial cells. Activating these receptors can reduce chronic inflammation, improve immune surveillance, and inhibit cell proliferation. In animal models, GLP-1 agonists have been shown to reduce tumor growth through direct effects on the tumor microenvironment.

A 2023 study in Cell Metabolism demonstrated that liraglutide enhanced the activity of natural killer cells in obese mice, leading to better clearance of implanted tumor cells. “The immune modulating effects of GLP-1 are underappreciated,” said Dr. Lenny K. Mishra, an immunologist at the University of Texas Southwestern Medical Center, in the Washington Post article. “These drugs may be doing much more than just helping people lose weight.”

Additionally, GLP-1 drugs reduce blood glucose and insulin levels. Hyperinsulinemia is a known promoter of cancer cell growth, especially in breast and colorectal tissues. By lowering insulin, GLP-1 agonists may remove a key growth signal.

Cautions and Limitations

Despite the encouraging signals, experts urge caution. The black box warning for medullary thyroid carcinoma remains in place, and some observational studies have reported a small but statistically significant increase in the risk of that specific cancer. However, the absolute risk is very low, and the link has not been confirmed in humans.

A meta-analysis published in 2024 in Diabetes Care pooled data from 23 randomized controlled trials and found no overall increase in total cancer incidence among GLP-1 drug users compared to placebo. But the trials were relatively short (median follow up of 2.3 years) and may not have been long enough to detect slowly developing tumors.

Another concern is that the observational studies showing cancer protection may be influenced by the “healthy user” effect. People who take GLP-1 drugs tend to be more engaged in their health, which could introduce bias.

“The most important evidence will come from long term randomized trials with cancer as a prespecified endpoint,” said Dr. Clifford J. Rosen, an endocrinologist at Maine Medical Center Research Institute, in the Washington Post article. “Until then, we should view these findings as hypothesis generating, not conclusive.”

Large outcomes trials already underway, such as the SELECT trial of semaglutide in cardiovascular disease, are now including cancer endpoints in their analysis. Results from SELECT are expected in mid 2025 and may provide more definitive answers.

Implications for Researchers and Health-Conscious Readers

For scientists, the evolving evidence underscores the need to study GLP 1 receptor agonists as potential chemopreventive agents. Several clinical trials are already testing semaglutide in patients at high risk for colorectal cancer, such as those with a history of adenomatous polyps. Biomarker studies are examining changes in colon mucosa gene expression after GLP 1 treatment.

For health-conscious readers, the findings add another dimension to the risk-benefit calculus of these medications. While weight loss and glucose control are proven benefits, the potential for cancer risk reduction may tip the scales for some individuals. However, these drugs are not without side effects, including nausea, vomiting, diarrhea, and the rare but serious risk of pancreatitis and gallbladder disease.

The Washington Post article that first brought this topic to public attention did not provide specific numbers or names, but it correctly captured the sense that the field is entering a new phase. As more data accumulates, the narrative around GLP-1 drugs is shifting from a simple diabetes and weight loss tool to a broader metabolic intervention that may influence long term health outcomes, including cancer.

Frequently Asked Questions

Q: What exactly are GLP-1 drugs and how do they work?

A: GLP-1 receptor agonists, such as semaglutide and liraglutide, are medications that mimic the natural hormone glucagon-like peptide 1. They stimulate insulin release, slow stomach emptying, and reduce appetite. They are used to treat type 2 diabetes and obesity. Their effects on body weight and metabolism may also influence cancer risk.

Q: Is there strong evidence that GLP-1 drugs reduce cancer risk?

A: Recent large observational studies, including a 2025 JAMA study of 1.6 million patients, have found an 11% to 18% reduction in certain obesity related cancers among GLP-1 users compared to people taking other diabetes drugs. However, these studies are observational, not randomized, so they cannot prove cause and effect. Long term clinical trials with cancer as a primary endpoint are still needed.

Q: Are there any cancer risks associated with GLP-1 drugs?

A: Yes. Animal studies led to a black box warning for medullary thyroid carcinoma. Human data remains mixed, but some observational studies have reported a small increase in thyroid cancer risk. The overall risk appears low, and most major studies have found no increase in total cancer incidence. Patients should discuss individual risk factors with their doctor.

Q: How might GLP-1 drugs lower cancer risk besides through weight loss?

A: Several mechanisms beyond weight loss are being investigated. These include reducing chronic inflammation, lowering insulin and insulin like growth factor levels, improving immune surveillance via natural killer cell activation, and direct effects on GLP-1 receptors in intestinal and immune cells. Preclinical studies support these non weight related pathways.